1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Ping Peng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orlistat Overcoming Third-generation EGFR-TKI Resistance Orlistat 120 mg - Lung Adenocarcinoma, Osimertinib | Phase 2 | Not yet recruiting | Ping Peng | 36 | 2025-02-16 | 2025-02-12 |
Orlistat (1)